Novartis Kisqali significantly prolongs life in women with HR+/HER2- advanced breast cancer now in two distinct Phase III trials
- In MONALEESA-3, Kisqali plus fulvestrant achieved statistically significant improvement in overall survival in post-menopausal women in first- and second-line setting?
- Kisqali is the only CDK4/6 inhibitor proven to prolong life with multiple combination partners?
- These results build on the unique MONALEESA-7 data presented at ASCO 2019 showing overall survival benefit of Kisqali plus aromatase inhibitor in pre-/peri-menopausal women?
- Full results will be presented at an upcoming medical congress and submitted to global health authorities
# # #
Novartis Global External Communications E-mail:?media.relations@novartis.comEric Althoff Novartis US External Communications +1 646 438 4335 eric.althoff@novartis.com | Julie Masow Novartis Oncology Media Relations +1 862 778 7220 (direct) +1 862 579 8456 (mobile) julie.masow@novartis.com |
Central | North America | ||
Samir Shah | +41 61 324 7944 | Richard Pulik | +1 862 778 3275 |
Pierre-Michel Bringer | +41 61 324 1065 | Cory Twining | +1 862 778 3258 |
Thomas Hungerbuehler | +41 61 324 8425 | ||
Isabella Zinck |